PATENT CLAIM ANALYSIS

Application Number: 15757687
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["424", "204100"]

Abstract:
The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.

Claim (Index 23):
A cancer immunotherapy method for treating cancer in a patient comprising:\n Isolating T lymphocytes from lymphoid tissue, peripheral blood or cancer tissue of the patient; optionally genetically engineering the T lymphocytes; stimulating the T lymphocytes to differentiate into effector lymphocytes in vitro; stimulating the effector T lymphocytes to proliferate in vitro; infusing the effector T lymphocytes back into the patient; and one or more of:\n administering an oncolytic virus to the patient after stimulating the effector T lymphocytes and prior to the infusing step; \n prior to the isolating step, administering the same or different oncolytic virus to the patient as a booster vaccine after vaccinating the patient with a vaccine comprised of the patient's own malignancy; \n prior to the isolating step, administering the same or different oncolytic virus to the patient as a prior to vaccinating the patient with a vaccine comprised of the patient's own malignancy; \n administering the same or different oncolytic virus to the patient after the infusing step; \n prior to the isolating step, administering the same or different oncolytic virus to the patient and then removing the patient's own malignancy prior to vaccinating the patient with the vaccine comprised of the patient's own malignancy; \n prior to the isolating step, removing the patient's own malignancy and then administering the same or different oncolytic virus to the patient prior to vaccinating the patient with the vaccine comprised of the patient's own malignancy; \n prior to the isolating step, removing the patient's own malignancy, combining the malignancy with the same or different oncolytic virus, and using the combined virus/malignancy to vaccinate the patient; and \n delivering the same or different oncolytic virus by the effector T lymphocytes in the infusion step.

Metadata:
- Claim Count in Document: 52.0
- Percentile: 90.0
- Lexical Diversity: 1.34884
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15892247', '14792424', '14004546', '15129916', '13470558']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7328919606276326
- 35 USC 102 Novelty (BERT): 0.5053272099696439
- Combined Prediction Score: 0.7101354855618337
- Mean Citation Score: 263.860032
- Max Citation Score: 281.17853
- Similarity Product: 212.45418319986527

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test